What is SCYX's health score?

SCYNEXIS INC (SCYX) has a TradeApes health score of 47 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is SCYX's estimated fair value?

Based on our 5-year discounted cash flow model, SCYNEXIS INC's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is SCYX undervalued or overvalued?

Our model currently rates SCYX as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for SCYX... Refresh in a moment for the full analysis.

SCYNEXIS INC (SCYX)

Healthcare Inconclusive inconclusive mixed

$4.85

Updated: 2026-06-05

TradeApes Score

Financial Strength

40 Weak

Operating Trend

65 Healthy

Relative Value

40 Weak

Capital Allocation

35 Weak

Risk

50 Mixed

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Altman Z-Score in distress zone — elevated bankruptcy risk

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.